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Abstract 
Associations between cannabis use and psychotic outcomes are consistently reported, but 
establishing causality from observational designs can be problematic. We review the 
evidence from longitudinal studies that have examined this relationship and discuss the 
epidemiological evidence for and against interpreting the findings as causal. We also review 
the evidence identifying groups at particularly high risk of developing psychosis from using 
cannabis.  
Overall, evidence from epidemiological studies provide strong enough evidence to warrant a 
public health message that cannabis use can increase the risk of psychotic disorders. 
However, further studies are required to determine the magnitude of this effect, the effect 
of different strains of cannabis on risk, and to identify high-risk groups particularly 
susceptible to the effects of cannabis on psychosis. We also discuss complementary 
epidemiological methods that can help address these questions. 
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Introduction 
Population studies consistently show that cannabis use is associated with psychotic 
experiences and disorders, including schizophrenia, but whether associations are causal is 
difficult to ascertain from observational designs. Randomised controlled trials in laboratory 
conditions provide evidence that delta-9-tetrahydrocannabinol (THC), the main active 
compound in cannabis, can induce transient psychotic-like experiences (1). However, these 
experiences resolve within a few hours and rarely cause distress, in contrast to psychotic 
disorder where experiences are prolonged and impairment often substantial.  
 
It is important to establish whether the association between cannabis and psychotic 
disorder is causal, and to accurately estimate the magnitude of this effect, as cannabis might 
represent the most potentially modifiable risk factor for psychosis. Non-causal explanations 
for associations arising from observational studies include reverse causation (where 
associations reflect psychosis increasing risk of using cannabis), bias (where problems with 
measurement or sample selection lead to incorrect estimates), and confounding (where 
other variables that increase risk of both cannabis use and psychosis lead to spurious 
associations), and are discussed further below.  
 
RCTs of cannabinoid use or interventions to reduce cannabis use tend to have follow-up 
periods too short to yield useful information about psychosis risk arising from long term use 
(2) and are not discussed further here. Nor do we review case-studies or studies relying on a 
diagnosis of cannabis-induced psychotic disorder, as such diagnoses are dependent on 
assumptions of a causal role of cannabis in specific cases by a clinician, and there is no 
robust evidence as far as we are aware of clinical characteristics that allow the distinction of 
this disorder to be made (3). 
 
 
Evidence from case control and cross sectional studies 
Evidence from most case-control and cross-sectional studies support an association between 
cannabis use and schizophrenia (4-6) and psychotic symptoms (7-9). A potential problem of 
case-control studies is selection bias arising from inadequate sampling of a control group, 
and in both these designs reverse causation cannot be excluded. Longitudinal or cohort 
studies provide a stronger design to examine evidence in support of a causal association. 
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Evidence from Cohort studies 
A 2007 systematic review identified 7 cohort studies investigating the association between 
cannabis use and schizophrenia, psychotic disorders or psychotic experiences (10). Since this 
publication, three more have been published. These 10 studies are described below and in 
Table 1. 
 
Studies investigating psychotic disorder: 
The Swedish Conscript Study found a dose-response relationship between cannabis use by 
age 18 and incident schizophrenia by age 45 (11, 12), with a 3-fold increase in risk in those 
who reported using cannabis more than 50 times by age 18 (95% CI 1.7, 5.5). 
 
In the Dunedin birth cohort study (13) cannabis use by age 15 was associated with an 
increase in schizophreniform disorder at age 26 (OR 11.4, 95% CI 1.8, 70.5), with a weaker 
association in those first using between age 15 and 18 (OR 2.0, 95% CI 0.8, 5.0), although 
confidence intervals were wide and overlapping. 
 
In the Dutch NEMESIS study (14) cumulative cannabis use was associated with incident 
psychotic outcomes measured 3 years later (OR 1.89, 95% CI 1.25, 2.85). A more recent 
study (15) extended these findings to also examine the risk of psychosis in ex-users of 
cannabis.  
 
The California Hospital Study reported a large association between hospital admission 
diagnosis of cannabis use disorder and risk of later hospitalisation for schizophrenia (16) 
compared to a cohort of subjects who were hospitalised for appendicitis (HR 8.16, 95% CI 
5.08, 13.12).  
 
Studies investigating psychotic experiences 
The Christchurch Health and Development study found evidence of an association between 
cannabis dependence and psychotic experiences after adjustment for numerous potential 
confounders (17, 18). The EDSP study found that any cannabis use at baseline was 
associated with psychotic symptoms 42 months later (19). In the ECA study (20) daily 
cannabis use was associated with increased risk of psychotic experiences, although there 
was little evidence that ever use of cannabis was associated with these experiences. In the 
NPMS (21) there was an association between cannabis dependence and incident psychotic 
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symptoms 18 months later in the unadjusted analysis, but this attenuated and CIs crossed 
the null after adjustment for confounders. 
 
The Zurich study followed a sample of participants for 30 years (22), finding weak evidence 
that cannabis use was associated with schizophrenia nuclear symptoms prior to, but not 
after, adjustment. In the ALSPAC birth cohort, cumulative cannabis use at age 16 was 
associated with psychotic experiences at age 18 after adjustment for pre-birth and 
childhood confounders (23). After further adjustment for cigarette use and other illicit drug 
use this association attenuated to the null, though the authors discuss the difficulty of 
teasing out confounding versus mediating effects, as well as the potential problem of over-
adjustment with such highly correlated measures. 
 
The 2007 meta-analysis (10) reported a 40% increase in risk (95% CI 20-65%) of any 
psychotic outcome in cannabis users compared to never users, and a stronger association 
with heavier or more regular cannabis use (OR 2.1, 95% CI 1.5, 2.8), or in studies only looking 
at psychotic disorder (OR for ever use of cannabis 2.6, 95% CI 1.1, 6.1). Updating the 
estimate for ever-use of cannabis to include adjusted results from the Zurich Study and 
ALSPAC (Californian Hospital Study omitted due to the extreme nature of the exposure 
measure), results in a very similar updated pooled odds ratio for any psychotic outcome of 
1.46 (95% CI = 1.24, 1.72; p<0.001; I
2
 = 19%).  
 
Interpretation of the findings 
The results from these longitudinal studies show a consistent pattern of association between 
cannabis and psychosis, which could be indicative of a causal relationship. However, there 
are a number of reasons why the studies described above might have overestimated or 
underestimated the association between cannabis and psychotic outcomes, which we 
consider below. 
 
 
 i) Confounding 
Residual confounding (i.e. over and above that accounted for in studies) would most likely 
lead to an overestimate of the true (causal) association, given that individuals who use 
cannabis regularly and those at higher risk of developing a mental illness share many similar 
characteristics. There is some evidence that residual confounding could still be present in 
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some of studies conducted to date, as studies of cannabis and psychosis that adjusted for 
more confounders showed greater attenuation of unadjusted estimates than those that 
adjusted for fewer, with attenuation of 60-80% of the unadjusted estimate in the 3 studies 
that adjusted most comprehensively for confounding (9).  Given the wide range of 
confounders adjusted for across studies to date it is not clear what factors might be leading 
to residual confounding. However, as an example, few studies have adjusted for measures of 
early life attachment, abuse and trauma. Whilst measurement error in any variables 
adjusted for would lead to residual confounding, such error is particularly likely for measures 
pertaining to these constructs. 
 
Shared genetic effects have also not been adequately adjusted for though it seems unlikely 
that this would explain the association observed given the small proportion of variance in 
cannabis use explained by common genetic variants for schizophrenia (24). A cross sectional 
study (25) reported an association between cannabis use duration and psychotic symptoms 
within sibling pairs, suggesting the association is not explained by genetic or shared 
environmental effects, whilst in the CHDS use of fixed-effects regression showed little effect 
of adjusting for unmeasured confounders that do not vary over time (though this does not 
account for unmeasured time-varying confounding) (17). However, a recent study (26) using 
a co-relative case-control design found that the association between cannabis disorder and 
schizophrenia became substantially smaller with increasing genetic relatedness from cousin-
pairs to monozygotic twins, suggesting that estimates from population studies may be over-
estimated due to genetic and shared environment effects. 
 
 ii) Bias 
Given the long half-life of THC, heavy users of cannabis may be rarely un-intoxicated, which 
could lead to misclassification of psychosis outcomes, and bias in estimating the association 
with psychotic outcomes that are not due to the direct effects of exogenous cannabinoids. 
Studies that assessed hospitalisation for schizophrenia are unlikely to be substantially 
affected by this bias (12, 16). Furthermore, a study using the NEMESIS cohort investigated 
the association between cessation of cannabis use and persistence of psychotic experiences 
as a way of minimising intoxication effects (15) and found (weak) evidence for an increase in 
psychotic experiences in former users compared to never users. However, there were very 
few ex-users in this sample, and further studies are required to examine this further. 
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 iii) Reverse causation 
Most longitudinal studies conducted to date have attempted to account for reverse 
causation by excluding those with psychotic symptoms at baseline or adjusting for baseline 
symptoms. Whilst it is possible that prodromal symptoms at baseline were not picked up by 
screening and could have led to increased cannabis use, this seems unlikely, especially 
where studies restricted analyses to examine outcomes occurring after a likely prodrome 
effect (e.g. 12). Furthermore, studies examining the association between psychotic 
experiences and incident cannabis use show much weaker and less consistent evidence than 
those examining cannabis use and incident psychotic experiences (17). 
 
Residual confounding, bias and reverse causation could have led to over-estimates of 
association. There are also a number of reasons why studies might have under-estimated 
true causal effects of cannabis on psychosis. 
 
 i) Misclassification bias 
Assessing use of cannabis accurately is challenging, and relying on self-report almost 
certainly introduces measurement error. If misclassification was random across the cohort, 
this would likely lead to an underestimation of association. If differential misclassification 
occurred, results could have been underestimated, for example if people who went on to 
develop psychotic experiences were less likely to report illicit drug use due to suspicious 
(non-psychotic) beliefs at baseline. If, conversely, those who developed psychosis were more 
candid or likely to exaggerate about their drugs use at baseline (e.g. due to cognitive 
impairments or personality traits), findings may have been overestimated. Furthermore, 
cannabis comes in a variety of types and strains, which contain numerous cannabinoids 
aside from THC. As there is some evidence that cannabidiol (CBD) has anti-psychotic effects 
(27-29), the lack of information on relative ratios of THC:CBD in these studies means that 
self-reported use will not accurately reflect levels of psychoactive compounds reaching the 
brain; again measurement error, if non-differential is likely to lead to an underestimate of 
association. Misclassification may be reduced by use of biomarkers such as hair samples 
though these also have limitations in that they only index recent and heavy cannabis use, 
providing a less accurate measure of long-term cumulative use than self-report measures. 
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 ii) Attrition 
Longitudinal studies are prone to attrition as participants are lost to follow up. Participants 
who use drugs and those with mental health problems are both more likely to drop out of 
longitudinal studies, and this could lead to selection bias (a differential effect between 
exposure and outcome) that would underestimate effects of cannabis on psychosis (30, 31). 
Whilst the CHDS, NEMESIS and ALSPAC studies all attempted to model for attrition, and 
found no evidence that this impacted on the findings (14, 17, 23), these methods rely on a 
number of assumptions, and bias cannot be entirely excluded. 
 
Identifying high risk groups 
Even if the association between cannabis and psychosis is causal, cannabis is neither 
necessary nor sufficient to cause psychotic disorder; risk factors for multifactorial complex 
diseases are not deterministic (32). For this reason, studies have tried to identify sub-groups 
that might be at particularly high risk from cannabis use.  
 
 Age of use 
In the Dunedin study, the authors stratified their findings by age of first use of cannabis (13), 
and found that participants who used cannabis by age 15 had a higher point estimate of 
association with schizophreniform disorder than those who used by age 18, suggesting the 
presence of a sensitive period of risk. However, CIs for the two groups overlapped 
substantially and were not directly compared, so findings are potentially consistent with 
sampling error. Furthermore, any difference, if present, could be driven by cumulative use: 
those who began using cannabis at an earlier age may have used cannabis more times by the 
time of the outcome measure than those who started using at a later age. 
 
In the Swedish Conscripts study, the authors assessed risk of schizophrenia stratified by age 
of first use of cannabis, whilst taking in to account cumulative use of cannabis. They found 
no evidence for a difference in risk by age of first use (10).  
 
There is some evidence from animal models that adolescence could be a critical period for 
development of the endocannabinoid system (33, 34). This system is involved in 
neuroplasticity and neurodevelopment, and cannabinoid CB1 receptor levels appear to 
fluctuate during adolescence in relation to brain development at this point (35). Therefore, 
whilst there is no strong evidence to support the hypothesis that cannabis is more harmful 
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to younger users, and that early adolescence is a sensitive period of risk, this remains an 
area of concern. 
 
 Genetic susceptibility 
In the Dunedin cohort cannabis use was found to have a substantially stronger effect on the 
risk of sczhiophreniform disorder on those people homozygous for the valine allele at rs4680 
(val
158
met) within the catechol-o-methyl-transferase (COMT) gene than those homozygous 
for methionine (36). However, this interaction was only seen in participants who first used 
cannabis prior to, and not after, age 18, raising concern that this might be a spurious finding. 
None of eight studies published since then replicate this (e.g. see 37, 38). More recently an 
interaction has been reported (39), and replicated in one study, between cannabis use and 
AKT1 on psychosis risk (40); however there are substantial concerns around gene 
environment interaction studies (38, 41), and currently evidence that effects of cannabis 
differ according to variation at AKT1 is not robust.  
 
 Childhood trauma 
Three studies have found that presence of both childhood trauma and cannabis use 
increased the absolute risk of psychosis to a greater degree than the sum of either risk factor 
alone (42-44). Although such findings could help inform which individuals are at higher risk 
of psychosis, such patterns of risk for co-exposure to two risk factors are the norm in multi-
factorial complex diseases (45, 46). 
 
 Strains of cannabis 
A number of studies indicate that cannabis strains containing higher THC:CBD ratios may 
result in greater risk of psychotic outcomes, and that CBD might have anti-psychotic 
properties (27-29, 47). A recent case-control study found that whilst ‘skunk’ cannabis (high 
THC:CBD) was associated with risk of a psychotic episode, ‘hash’ cannabis (low THC:CBD) 
was not (48). This is an important emerging area of research, which could provide a target 
for campaigns if studies corroborate the finding that different strains of cannabis confer 
different risk of psychosis. However, given that studies conducted before skunk became 
widely used also showed an association between cannabis and psychosis, it is too early to 
assume that only skunk, but not lower potency forms of cannabis are associated with 
psychosis risk. Longitudinal studies of long-term effects of skunk versus hash, with accurate 
measures of THC and CBD are required, but will need to address the possibility that 
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participants are selecting to an extreme of use (heavy cannabis use in earlier studies, and 
stronger cannabis use as it became available) as a result of other characteristics that are 
(independently) associated with psychosis risk (49). 
 
These studies have increased concern that as levels of THC in cannabis have altered over the 
past few decades (50-52), results from earlier studies could be underestimating the impact 
of the effects of cannabis on psychosis that exist today. Corroborating ecological evidence 
that psychosis risk has increased recently in young people exposed to higher THC than 
earlier birth cohorts has not been examined (53).  
 
There is also increasing concern about the psychotogenic effects of synthetic cannabinoids, 
currently from case reports of individuals experiencing psychosis after using them (54). 
Given this, there is a strong need for more robust epidemiological studies to determine the 
likely impact of synthetic cannabinoids on risk of psychotic disorders. 
 
Evidence in support of causation 
There are a number of facets of the evidence presented above that are consistent with a 
causal association between cannabis and psychosis. The longitudinal, case-control and cross-
sectional studies conducted to date have, for the most part, found consistent evidence of an 
association, even after adjustment for covariates. Those that assessed a dose-response 
relationship have found evidence for this. The experimental evidence showing that psychotic 
experiences occur during cannabis intoxication (1) indicates that cannabis has biological 
effects that could translate to chronic psychotic disorders. Neurobiological evidence on the 
effect of cannabis use, which includes dopaminergic, glutaminergic, and GABA activity 
modulation, are broadly consistent with the current understanding of neurobiology of 
psychotic disorders (55), as discussed in other articles in this issue (refs). 
 
There is also indirect evidence that supports causality. For example, a number of studies (12-
14), although not all (16, 23) found evidence for specificity of exposure, namely that 
associations between other drug use and psychosis are weaker than for cannabis. There is 
also some evidence of specificity of outcome (10, 56) though this is not seen in all studies 
(57). 
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Evidence inconsistent with a causal relationship 
Given that cannabis use has increased greatly since the 1960s, an argument made against a 
causal association between cannabis and schizophrenia is that a corresponding increase in 
schizophrenia diagnoses has not been observed. Some studies have found that incidence of 
psychotic outcomes has increased in recent decades (58, 59), while others have found no 
change, or a decrease (60, 61). Ecological evidence such as this provides only very weak 
evidence for causality, as it cannot be ascertained whether individuals using cannabis are the 
same as those experiencing psychosis (the ecological fallacy), studies are unable to account 
for likely confounders, and do not account for other potentially competing risk factors for 
schizophrenia that may have declined over the same time period. 
 
Addressing the uncertainty 
With observational data there is always likely to be some uncertainty as to whether cannabis 
has a causal effect on chronic psychotic disorders such as schizophrenia. Although criteria 
often used to establish causality, including temporal distinction between exposure and 
outcome, strength and direction of association, biological gradient, consistency, specificity, 
coherence, experimental evidence, and biological plausibility are all met, there are examples 
in epidemiology where associations conforming to these criteria have turned out to be 
confounded when RCTs have been conducted (62).  
 
Currently there remains a need for stronger evidence to address questions regarding the 
magnitude of causal effect on risk of psychotic disorders, the impact of different strains of 
cannabis, and to identify any groups at particularly high risk of developing psychosis 
following use of cannabis. Furthermore although we have only focused on positive psychotic 
symptoms in this article schizophrenia is also characterised by other clinical features such as 
cognitive impairment. Whilst cognitive deficits have also been shown to be associated with 
cannabis use (63) these studies suffer from the same issues as discussed above regarding 
establishing whether association from observational studies are causal or not.  
Different epidemiological approaches may be required to help address these remaining 
uncertainties, particularly in relation to residual confounding.  For example, it may be 
possible to conduct large, cluster-randomised trials to investigate long-term psychosis 
outcomes following substance use interventions. Although interventions are of limited 
efficacy and such trials are unlikely to be a pragmatic solution at present this may change as 
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more effective interventions are developed. Linkage of electronic registers to capture long-
term outcomes from trial participants might also make such approaches more feasible in the 
future. Furthermore, as cannabis is legalised in some States of the USA, experimental studies 
of cannabis may become easier to undertake. 
 
Observational studies across populations with differing underlying confounding structures 
(cross-cohort studies) may also help address questions of residual confounding. For 
example, breastfeeding, which is socially patterned in the UK but not in Brazil, was found to 
be associated with obesity only in the UK sample, whereas the association with IQ was 
observed in both the UK and Brazilian samples, indicating that the association with obesity is 
likely to be due to residual confounding, whilst that for IQ is more likely to be causal (64). 
 
Mendelian randomisation, where genetic information is used as a proxy for an exposure of 
interest, could also be used as a method to minimise confounding (65). However, there are 
important limitations to Mendelian randomisation currently, in particular that genetic 
variants that robustly predict cannabis use have yet to be identified (65). 
 
 
Implications 
If the association between cannabis and schizophrenia is causal and of the magnitude 
estimated across studies to date (10), this would equate to a schizophrenia lifetime risk of 
approximately 2% in regular cannabis users (though risk for broader psychotic outcomes will 
be greater). This implies that about 98% of regular cannabis users will not develop 
schizophrenia, and therefore cannabis cessation interventions would need to prevent very 
large numbers from using cannabis in order to meaningfully effect incidence of 
schizophrenia. However, risk could be much greater in those at a higher genetic risk (66), or 
in those who use particularly potent strains of cannabis (48). For example, if regular 
cannabis use increased the risk of schizophrenia two-fold, and assuming the pattern of risk 
for co-exposure to cannabis and high genetic risk is approximately multiplicative, as it is for 
most risk factors for multifactorial complex disorders, then the lifetime risk in individuals 
with a first degree relative if they use cannabis regularly could be around 20%. 
 
As cannabis exposure has increased then so should the attributable fraction of 
schizophrenia. From epidemiological studies to date, the population attributable fraction 
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(assuming causality) could be 10-25% depending on whether risk is confined to heavy 
cannabis or all users (10) . However, the absolute number of cannabis users needed to stop 
using cannabis in order to prevent one case of schizophrenia per year has been estimated at 
approximately 5000 for heavy users among men, and 10,000 to 15,000 among women (67). 
Given that current treatments for cannabis dependence have approximately 20% efficacy 
(68), these figures may need to be multiplied by five in order to give a meaningful number 
needed to treat. These figures will be lower if calculating risk of schizophrenia over the 
entire lifespan rather than over one year, and if considering broader psychosis outcomes 
(although most clinical interest is on severe outcomes where suffering is greatest). An 
effective public health campaign would be better placed trying to prevent people from 
taking up cannabis use or progressing to heavier use, than to stop current users, similar to 
tobacco prevention programmes (69).  
 
There is no doubt that a public health message that cannabis use is harmful is appropriate. 
However clear communication of the risks of cannabis is needed, as a public health 
campaign that is ignored by those who it is aimed at has little value. Whilst it is important to 
avoid understating potential harms, which could put peoples’ health at risk, it is also 
important to avoid overstating the harms of cannabis, which could lead to the message 
being ignored when experience does not match the warnings given. 
 
Conclusion 
Although there is always uncertainty when observational studies are relied on for evidence 
of causation, there is a strong body of epidemiological evidence to support the view that 
regular or heavy cannabis use increases the risk of developing psychotic disorders that 
persist beyond the direct effects of exogenous cannabinoids. However, in order to reduce 
uncertainty and obtain more accurate estimates of risk, multiple complementary techniques 
are required. Critically, cannabis exposure among adolescents and young people is common 
and psychosis remains rare – further evidence is required in order to characterise the 
population at greater risk of psychosis if exposed to cannabis. Only through robust 
converging evidence across neurobiology and observational epidemiology disciplines, 
including new techniques to better investigate causation from these data, can a clearer 
understanding of the relationship between cannabis and psychosis be elucidated. 
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Table 1 Description of the longitudinal studies on cannabis and psychotic outcomes 
published to date 
Cohort 
 
Sample 
size 
(and 
with 
outcom
e) 
Exposure Outcome Results 
(adjuste
d) 
OR(95% 
CI) 
Strengths Limitation
s 
ECA (20) 2295 
(477) 
Daily use of 
cannabis 
(binary) 
Psychotic 
experiences 
(binary) 
2.0 
(1.25, 
3.12) 
Large sample 
size, 
interview-
based 
psychotic 
experiences 
measure 
No 
attempt to 
account 
for 
intoxicatio
n 
NEMESIS 
(14) 
4045 
(38) 
Ever use 
and 
frequency 
of use 
Psychosis 
symptoms 
(severity) 
2.76 
(1.18, 
6.47) 
Legality of 
cannabis use 
in 
Netherlands; 
investigation 
of self-
medication 
hypothesis; 
attempt to 
remove 
intoxication 
effect; large 
sample size; 
repeated 
measures of 
exposure and 
outcome 
Sample 
size too 
small to 
examine 
psychotic 
disorders 
robustly 
Swedish 
cohort 
(12) 
50087 
(362) 
Cumulative 
cannabis 
use 
Schizophrenia 
diagnosis 
Linear 
trend  
1.2 (1.1, 
1.4) 
Large sample 
size, attempt 
to remove 
intoxication 
effect, 
schizophrenia 
measure 
Only males 
included, 
therefore 
results 
may not 
be 
generaliza
ble; large 
temporal 
gap 
between 
exposure 
and 
outcome, 
could miss 
variation 
in 
cannabis 
use; low 
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levels of 
cannabis 
use at 
baseline 
Dunedin 
(13) 
759 
(25) 
Ever use of 
cannabis by 
age 15/18 
Schizophrenif
orm diagnosis 
2.91 
(1.20, 
7.04) 
Strong cohort 
retention, 
minimising 
possibility of 
attrition bias; 
schizophrenif
orm disorder 
measure 
Small 
sample 
size, 
exacerbate
d by 
dividing 
sample in 
to 
cannabis 
before/aft
er 15; 
limited 
adjustmen
t for 
confoundi
ng;  
Christchu
rch (17, 
18) 
1265 Cannabis 
use; 
dependenc
e 
Psychotic 
experiences  
1.8 (1.2, 
2.6) 
Thorough 
consideration 
of 
confounders; 
use of fixed-
effects 
regression to 
minimize 
confounding 
by time 
invariant 
confounders 
Lack of 
clinical 
measure 
of 
psychosis; 
small 
sample 
size. 
EDSP (19) 2437 
(424) 
Used at 
least 5 
times 
Psychotic 
symptoms  
1.2 (1.1, 
1.3) 
Investigation 
of reverse 
causation 
hypothesis;  
 Sample 
size too 
small to 
examine 
psychotic 
disorders 
robustly? 
NPMS 
(21) 
1795 
(134) 
Dependenc
e (3-level 
measure) 
Self-reported 
psychotic 
symptoms 
1.5 (0.6, 
3.9) 
Thorough 
consideration 
of 
confounders 
Few 
cannabis 
users; 
sample 
selected 
due to pre-
existing 
mental 
health 
problems 
so may not 
be 
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generalisa
ble 
Rossler 
(22) 
591 
[2200 
(221) 
records
] 
Heaviness 
of use (3-
level 
measure) 
Schizophrenia 
nuclear 
symptoms 
(self-report) 
Adjusted 
results 
not 
reported 
– 
unadjust
ed 1.77 
(0.96, 
3.24 
Many 
repeated 
measures 
over long 
follow up;  
Small 
sample 
size; 
limited 
considerati
on of 
confounde
rs 
California 
(16) 
41670 
(174) 
Hospitalisat
ion for 
cannabis 
abuse 
Hospitalisatio
n for 
schizophrenia 
8.2 (5.1, 
13.1) 
Large sample 
size;  
Extreme 
exposure 
measure; 
limited 
considerati
on of 
confounde
rs 
ALSPAC 
(23) 
1756 
(97) 
Cumulative 
use (4-
level) 
Psychotic 
experiences 
severity (4-
level) 
1.12 
(0.76, 
1.65) 
Thorough 
consideration 
of 
confounders 
Small 
sample 
size; 
correlation 
of 
covariates; 
young age 
of 
participant
s; lack of 
clinical 
measure 
of 
psychosis 
 
 
